StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Rebates Provision Charged Against Gross Product Sales by Year

Rebates Provision Charged Against Gross Product Sales ($M) ($M)

Amgen Rebates Provision Charged Against Gross Product Sales: $21,697M in FY2025, up 24.7% from a year earlier. That is the highest of the 12 years on record here.

Latest, FY2025
21,697
Period ended Dec 31, 2025
Change on a year earlier
+24.7%
17,404 in FY2024
History
12 years
Since FY2014
Sources
10
Documents cited below

Where the FY2025 figure comes from

“|| Amounts charged against product sales | 21,697 | 16,988 | 3,298 | 41,983”

Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-K Item 7 MD&A Gross-to-Net Sales Deductions Rollforward.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRebates Provision Charged Against Gross Product Sales ($M) ($M)Year on yearSource
FY2025Dec 31, 202521,697+24.7%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2024Dec 31, 202417,404+21.5%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2023Dec 31, 202314,328+14.6%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
FY2022Dec 31, 202212,500+22.6%Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗
FY2021Dec 31, 202110,195+11.2%Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗
FY2020Dec 31, 20209,167+34.3%Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗
FY2019Dec 31, 20196,825+10.4%Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗
FY2018Dec 31, 20186,180+25.9%Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗
FY2017Dec 31, 20174,909+41.1%Form 10-K (amgn-12312019x10kq42019.htm, filed 2020-02-12) ↗
FY2016Dec 31, 20163,479+27.2%Form 10-K (amgn-12312018x10kq42018.htm, filed 2019-02-13) ↗
FY2015Dec 31, 20152,734+9.4%Form 10-K (amgn-12312017x10k.htm, filed 2018-02-13) ↗
FY2014Dec 31, 20142,499–Form 10-K (amgn-12312015x10k.htm, filed 2016-02-16) ↗

Cite this data

StockData. (2026). Amgen Rebates Provision Charged Against Gross Product Sales ($M), annual FY2014–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn-prov-rebates

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.